Revisiting Li-Fraumeni Syndrome From TP53 Mutation Carriers

Gaëlle Bougeard; Mariette Renaux‐Petel; Jean‐Michel Flaman; Camille Charbonnier; Pierre Fermey; Muriel Belotti; Marion Gauthier‐Villars; Dominique Stoppa‐Lyonnet; Émilie Consolino; Laurence Brugières; Olivier Caron; Patrick R. Benusiglio; Brigitte Bressac–de Paillerets; Valérie Bonadona; Catherine Bonaïti‐Pellié; Julie Tinat; Stéphanie Baert‐Desurmont; Thierry Frébourg

doi:10.1200/jco.2014.59.5728

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

The clinical gradient of the germline TP53 mutations, which should be validated by other studies, suggests that it might be appropriate to stratify the clinical management of LFS according to the class of the mutation.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Bougeard et al. (2015) studied this question.

synapsesocial.com/papers/69dcb93925b1b6cb33359928 https://doi.org/10.1200/jco.2014.59.5728

View at Publisher

Ask AI

Bookmark

Share

Revisiting Li-Fraumeni Syndrome From TP53 Mutation Carriers

Ask about this paper

Abstract

Discussion

Cite This Study

Revisiting Li-Fraumeni Syndrome From TP53 Mutation Carriers

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading